Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1βand sCD200 in cases of Samter's syndrome: 36 months follow-up

Abstract

To our knowledge, this is the first time an association between omalizumab use and Samter's syndrome has been documented. As a conclusion allergic nasal symptoms (sneezing, postnasal drip) and asthma symptoms were decreased in patients, but no change was seen on nasal polyposis development after omalizumab treatment.

Soluble CD200 Correlates With Interleukin-6 Levels in Sera of COPD Patients: Potential Implication of the CD200/CD200R Axis in the Disease Course

“…There exist soluble (s) forms of CD200 and its receptor CD200R in human sera [16] and Samter´s syndrome [22]. The fact that the level of sCD200 in serum is elevated in several diseases might indicate both a possible implication of the CD200/CD200R axis in inflammatory diseases and also imply a potential use of sCD200 as a biomarker.…”

Effects of Omalizumab Treatment on Some Biomarkers in Severe Allergic Asthma Patients

“…In a previous study, OX2 levels were altering owing to the clinical condition of patients that might be on account of playing the role of pathogenesis of autoimmune/inflammatory diseases (17, 18). Our observations on the patients seem to be supporting the role of OX2 as a pro-inflammatory molecule such as IL-1β (8,19,20). Thus, the increased levels of OX2 seen in our study with active disease (Group 1A) presumably represent a manifestation of a homeostatic response directed to the control of inflammation.…”

“…Conversely, there was no change in IL-1β levels between the groups and omalizumab had no effect on IL-1β levels. Controversial to prior studies showing a decrease on IL-1β levels in severe asthmatics, no change in the concentration might be caused in patients having asthma and shorter treatment periods (19,20,26).…”

ANTI-Ige: An Overview

“…After the second round of omalizumab (300 mg), frequency of exacerbations decreased and after 13th round it was completely disappeared [58]. Reduction in serum levels sOX-2 with anti-IgE treatment suggests that sOX-2 could be pro-inflammatory [21,24,47,57,58]. Soluble OX-2 might also play a role in immune response in the pathogenesis of autoimmune and inflammatory skin disorders [60,61].…”

“…Omalizumab has been approved in over 120 countries for treating patients with SPA. These pharmaceutical developments have validated the IgE pathway as an effective therapeutic target for treating IgE-mediated allergic disease [23][24][25].…”